Benralizumab outperforms mepolizumab in IgE reduction for severe eosinophilic asthma

Benralizumab reduced levels of IgE circulating in the blood among patients with severe eosinophilic asthma but mepolizumab did not, according to a study published in Clinical and Translational Allergy.
These humanized monoclonal antibodies inhibit eosinophil-driven inflammation, Marco Contoli, MD, PhD, associate professor in the section of respiratory medicine in the department of translational medicine at University of Ferrara in Ferrara, Italy, and colleagues wrote.
Mepolizumab (Nucala, GlaxoSmithKline) does so by blocking IL-5, whereas benralizumab (Fasenra, AstraZeneca) blocks one of IL-5’s

Benralizumab reduced levels of IgE circulating in the blood among patients with severe eosinophilic asthma but mepolizumab did not, according to a study published in Clinical and Translational Allergy.
These humanized monoclonal antibodies inhibit eosinophil-driven inflammation, Marco Contoli, MD, PhD, associate professor in the section of respiratory medicine in the department of translational medicine at University of Ferrara in Ferrara, Italy, and colleagues wrote.
Mepolizumab (Nucala, GlaxoSmithKline) does so by blocking IL-5, whereas benralizumab (Fasenra, AstraZeneca) blocks one of IL-5’s